Literature DB >> 6692656

Baroreflex setting and sensitivity after acute and chronic nicardipine therapy.

M A Young, R D Watson, W A Littler.   

Abstract

Intra-arterial pressure, baroreflex sensitivity and the baroreflex set point were measured in eight patients with essential hypertension during a control period and then after acute treatment (2 h after a 30 mg oral dose) and after chronic treatment (at least 2 months) with nicardipine hydrochloride, a calcium channel antagonist. Mean intra-arterial blood pressure fell after the acute treatment from 130 +/- 14 (SD) control to 118 +/- 11 mmHg, P less than 0.05, and after chronic treatment to 112 +/- 19 mmHg, P less than 0.05. Heart rate increased from 72 +/- 11 control to 81 +/- 16 beats/min, P less than 0.05, during acute treatment indicating activation of the baroreflex control mechanism, but returned to control values with chronic treatment (72 +/- 11 control vs 69 +/- 9 beats/min chronic), indicating a significant shift to the left of the baroreflex set point. There was no change in baroreflex sensitivity after either acute or chronic treatment (control 4.7, acute 4.3, chronic 5.1 ms/mmHg, P not significant for all values). Nicardipine significantly reduces mean intra-arterial pressure both acutely and chronically; the latter is associated with a return of the heart rate to control values due to resetting of the baroreflex control mechanism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692656     DOI: 10.1042/cs0660233

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  20 in total

1.  The cardiovascular effects of oral nifedipine and nicardipine: a double-blind comparison in healthy volunteers using transthoracic bioimpedance cardiography.

Authors:  S H Thomas; P Molyneux; J Kelly; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

3.  Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nicardipine.

Authors:  P A Broadhurst; G Brigden; M Heber; A Lahiri; E B Raftery
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

4.  Effect of nicardipine on haemodynamic response to stress in hypertension.

Authors:  T Takabatake; Y Yamamoto; S Nakamura; N Hashimoto; S Satoh; Y Yamada; K Kobayashi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Vascular haemodynamic effects of perindopril in essential hypertension.

Authors:  W Littler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

7.  The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension.

Authors:  J Levenson; A C Simon; J Bouthier; B C Maarek; M E Safar
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

9.  The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects.

Authors:  F Pasanisi; P A Meredith; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Nicardipine HCl: clinical experience in patients undergoing anaesthesia for intracranial aneurysm clipping.

Authors:  D S Warner; M D Sokoll; M Maktabi; J C Godersky; H P Adams
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.